Journal of Clinical Oncology, Vol 15, 1880-1884, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study

JA Sparano, D Neuberg, JH Glick, NJ Robert, LJ Goldstein, GW Sledge and W Wood
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467, USA. sparano@jimmy.harvard.edu

PURPOSE: To determine the efficacy of a biweekly paclitaxel and cisplatin regimen in patients with advanced breast carcinoma, which has previously been reported to produce an 85% response rate in such patients. PATIENTS AND METHODS: Sixteen patients with metastatic breast carcinoma who had relapsed after prior doxorubicin-containing adjuvant chemotherapy were treated with paclitaxel (90 mg/m2) by intravenous (i.v.) infusion over 3 hours followed by cisplatin (60 mg/m2) given by i.v. infusion over 1 hour on an outpatient basis. Treatment was repeated every 2 weeks if the absolute neutrophil count was > or = 750/microL and platelet count > or = 75,000/microL. After a maximum of eight cycles of paclitaxel/cisplatin, patients received biweekly paclitaxel alone (90 mg/m2 with dose escalation). Thirteen patients were assessable for response and all for toxicity. Nine of 13 patients assessable for response (69%) had at least three sites of metastases and 10 patients (77%) had visceral-dominant disease. RESULTS: Partial response occurred in three of 13 assessable patients (23%; 90% confidence interval, 7% to 49%). All responders had two or fewer sites of metastases. The median time to progression was 4.3 months and the median survival duration was 11.4 months. Patients received a median of seven cycles of therapy (range, two to 21). Severe and/or life- threatening toxicity occurred in 50% and 38%, respectively, and consisted primarily of granulocytopenia, anemia, and neuropathy. The trial was terminated after the first interim analysis as per its two- stage design, since it was unlikely that the response rate would exceed 70%. CONCLUSION: Biweekly paclitaxel/cisplatin is not likely to produce a response rate greater than 70% in patients with metastatic breast cancer who have relapsed after prior doxorubicin-containing adjuvant chemotherapy and who have multiple sites of metastases and/or visceral- dominant disease.

This article has been cited by other articles:

				Y.-C. Lin, H.-K. Chang, J.-S. Chen, H.-M. Wang, T.-S. Yang, and C.-C. Liaw A Phase II Randomized Study of Two Taxanes and Cisplatin for Metastatic Breast Cancer after Anthracycline: A Final Analysis Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 23 - 29. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				E. A. Perez Paclitaxel in Breast Cancer Oncologist, December 1, 1998; 3(6): 373 - 389. [Abstract] [Full Text]